Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

INDIVUMED, INC.

UEI: L5JBA83NAK17

INDIVUMED, INC. is a federal contractor, registered under UEI L5JBA83NAK17. It has been awarded $2,308,558 in federal contracts. Primary work spans In-Vitro Diagnostic Substance Manufacturing, Blood and Organ Banks, and Other NAICS codes (1 codes, <0.5% each). Top awarding agencies include Department Of Health And Human Services.

Contact Information

Registration and classification details

Registration

UEI Code

L5JBA83NAK17

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

Key Performance Metrics

Awards Count

6

All time

Active

0

Currently performing

Completed

6

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency
Awards by NAICS
Awards by Agency Over Time
Awards by Place of Performance

Compete with INDIVUMED, INC.

Track the contractors you bid against, and the work they win

Award history, agency mix, and NAICS coverage for INDIVUMED, INC.

AI-powered matching against your own capabilities and past performance

Teaming and subcontracting signals on every award

Automated alerts when a competitor wins in your market

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS

Open opportunities in INDIVUMED, INC.'s top NAICS codes and agencies

NAICS: 325413
New
Federal
Cost Per Reportable Result Purchase of Immunohistochemistry Reagents for Laboratory Tests.
Solicitation # 36C26027Q0058
The Department of Veterans Affairs, through Network Contracting Office 20, is seeking a comprehensive histology staining workflow system for the Puget Sound Health Care System in Seattle, Washington. The required system must include two immunohistochemistry and two in-situ hybridization immunostainers, two special stainers, and an integrated specimen tracking system to ensure patient safety, maintain a chain of custody, and monitor productivity. The workflow components must be fully automated, communicate with one another, and maintain compatibility with Data Innovations middleware as well as VISTA, Cerner, and any future electronic health record systems acquired by the VA. The contract follows a Cost Per Reportable Result pricing model and spans a base year from February 1, 2027, to January 31, 2028, with four subsequent one-year option periods extending through January 31, 2032. Technical requirements specify that the immunostainers must perform 100% of tests listed in the provided specifications and support simultaneous IHC, ISH, and Direct Immunofluorescence staining. Equipment must support Code 39 and Code 128 barcodes, include a safe hazardous waste removal system, and be provided with an uninterruptible power supply capable of supporting a 15-minute controlled shutdown. The contractor is responsible for the delivery, installation, and removal of equipment at no additional charge and must guarantee a minimum equipment uptime of 98%. Performance and method validation must adhere to CLSI guidelines and College of American Pathologists standards. Additionally, the contractor must comply with strict federal and VA information security directives, including those regarding data confidentiality and media sanitization. Emergency supply orders must be fulfilled within 24 hours of a verbal request, providing enough consumables for one week of normal operation.
260-NETWORK Contract Office 20 (36C260)

POSTED

2 days ago

DEADLINE

in 23 days
View Details
NAICS: 621991
New
Federal
Human Cadaver - Based Medical Training and Program Support Services for the 44th Medical Brigade stationed at Fort Bragg Army Base, North Carolina.
Solicitation # 0012468284
The Medical Acquisition Support Office – Alpha is seeking capable vendors to provide human cadaver-based medical training and program support for the 44th Medical Brigade. The scope of work includes the procurement and delivery of up to 20 ethically sourced, non-dissected perfused whole-body cadaver specimens annually, which must be serologically negative for HIV, Hepatitis B/C, and Syphilis. The contractor is responsible for providing refrigerated transportation to primary performance sites at Fort Bragg, NC; Fort Campbell, KY; Fort Stewart-Hunter Army Airfield, GA; and Fort Polk, LA. Additionally, the contractor must provide rental medical equipment and consumable Class VIII supplies, such as surgical packs, tourniquets, and simulated blood. The requirement includes providing highly qualified Subject Matter Experts (SMEs) to support up to 10 training events per fiscal year. These SMEs must be board-certified general surgeons with specific competencies in various trauma procedures, such as cricothyroidotomy and exploratory laparotomy, to serve as instructors and mentors. The anticipated contract structure consists of a base period followed by four one-year option periods. All personnel must comply with strict Installation Access Control System requirements, including Anti-Terrorism Level I and iWatch training, to gain access to military installations.
W40M MRC0 West

POSTED

2 days ago

DEADLINE

in 10 days
View Details
NAICS: 325413
New
Federal
6550--HEMOCHRON SIGNATURE ELITE REAGENTS AND SUPPLIES
Solicitation # 36C26227Q0046
The Department of Veterans Affairs, Network Contracting Office 22, is conducting a sources sought notice for the procurement of FDA approved reagents, supplies, consumables, and quality control materials for Werfen Hemochron Signature Elite instruments. This requirement supports the Pathology and Laboratory Medicine Service at the Southern Arizona VA Health Care System in Tucson, Arizona. The contract structure includes a base year from January 1, 2027, to December 31, 2028, followed by four subsequent option years extending through December 31, 2032. The selected contractor must provide 24/7 technical and product support at no additional cost and ensure all items are fully compatible with existing instrumentation without requiring workflow changes or retraining. Key operational requirements include strict adherence to manufacturer specifications for packaging and temperature control during transport. All supplied materials must maintain a minimum shelf life of 90 days, and shipments must clearly list lot numbers and expiration dates. Standard orders are required to be delivered within four working days, while emergency deliveries for defective or temperature-compromised items must be completed within 24 hours of a verbal order. This procurement is conducted as a brand name or equal acquisition under FAR 52.211-6. Interested respondents must provide their business size status, SAM.gov identifiers, and evidence of compliance with the Buy American Act and the Non-Manufacturer Rule.
262-NETWORK Contract Office 22 (36C262)

POSTED

3 days ago

DEADLINE

in 13 days
View Details
NAICS: 621991
New
Federal
6505--Human Blood and Blood Products
Solicitation # 36C25727Q0049
The Department of Veterans Affairs, Network Contracting Office 17, intends to award a single-award, firm-fixed-price Indefinite Delivery/Indefinite Quantity (IDIQ) contract to the South Texas Blood and Tissue Center. This procurement is for the supply and delivery of human blood and blood products, as well as guidance in clinical pathology procedures, to support the Audie L. Murphy Veterans Health Care Center within the South Texas Veterans Health Care System in San Antonio, Texas. The government is pursuing this as a sole source procurement under the authority of 41 U.S.C. 3304(a)(1) and FAR 6.103-1, asserting that only one responsible source can satisfy the agency's requirements. The contractor must maintain AABB and College of American Pathologists (CAP) accreditation and hold an unrevoked U.S. license from the FDA Bureau of Biologics. Key operational requirements include 24/7/365 availability and a tiered delivery system: STAT orders must be delivered within 60 minutes, ASAP orders within 2 hours, and routine orders within 24 hours. All products must be collected via closed systems under aseptic conditions, labeled according to the ABO Blood Group System and Rh type, and transported in compliance with FDA, AABB, and DOT regulations to ensure proper temperature maintenance. Acceptance of deliveries is based on STVHCS Blood Bank criteria, including physical appearance, contamination checks, and specific shelf-life minimums for red blood cells, plasma, and cryoprecipitate.
257-NETWORK Contract Office 17 (36C257)

POSTED

6 days ago

DEADLINE

in 15 days
View Details
NAICS: 621991
New
Grant
Limited Competition: Biospecimen Banks to support NCI National Clinical Trials Network Biospecimen Banks (NCTN Biobanks) and the NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) (U24 Clinical Trial Not Allowed)
Solicitation # RFA-CA-28-004
The National Cancer Institute (NCI) has issued a Limited Competition Notice of Funding Opportunity (RFA-CA-28-004) to support the continuation of two critical biospecimen banking resources: the National Clinical Trials Network (NCTN) Biobanks and the Early-Phase and Experimental Clinical Trials (EET) Biobank. The primary objective is to maintain these national resources for the collection, processing, storage, and distribution of high-quality, clinically annotated human biospecimens. These resources facilitate translational cancer research, biomarker development, and validation by providing essential specimens from NCI-funded clinical trials. The NCI intends to fund approximately six awards for fiscal year 2027, with a total estimated funding of 19 million dollars and a maximum budget of 3 million dollars in direct costs per year for a requested project period of six years. Applications will be evaluated through the NIH peer-review system based on scientific and technical merit, significance, and the adequacy of the institutional environment. Key requirements for applicants include maintaining active registrations in SAM, eRA Commons, and Grants.gov, as well as providing specific documentation regarding the current scale of operations, accomplishments, and standard operating procedures. Awardees must adhere to NCI Best Practices for Biospecimen Resources, federal human subjects regulations under 45 CFR 46, and strict cybersecurity incident reporting protocols, including notification of incidents within 48 hours of discovery. The scope of work includes managing secure informatics systems, providing specimen collection kits, and ensuring the availability of annotated biospecimens for authorized investigators.
National Institutes Of Health

POSTED

6 days ago

DEADLINE

in 4 months
View Details
NAICS: 621991
New
Grant
Limited Competition: Biospecimen Banks to support NCI National Clinical Trials Network Biospecimen Banks (NCTN Biobanks) and the NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) (U24 Clinical Trial Not Allowed)
Solicitation # RFA-CA-28-004
The National Cancer Institute is issuing a limited competition Notice of Funding Opportunity, solicitation RFA-CA-28-004, to support the continuation of two critical biospecimen banking resources. These resources include the National Clinical Trials Network Biobanks, which support the NCTN and the Community Oncology Research Program, and the Early-Phase and Experimental Clinical Trials Biospecimen Bank, which supports the ETCTN and other early-phase experimental trials. The primary objective is to maintain national infrastructure for the collection, processing, storage, and distribution of high-quality, clinically annotated human biospecimens to enable translational cancer research, biomarker development, and the study of drug response and resistance. Eligible organizations must submit applications by February 12, 2027, to be considered for funding. All submissions will undergo a standard NIH peer-review process, and only meritorious applications will be selected. These banks are essential for linking biospecimens to clinical outcome data from large multi-site trials and supporting the development of novel cancer therapies through pharmacokinetic and pharmacodynamic analyses.
National Cancer Institute

POSTED

6 days ago

DEADLINE

in 4 months
View Details